Metamizol Ratiopharm

Metamizole sodium, the active ingredient in Metamizol Ratiopharm, is a pyrazolone presented as an oral tablet for oral use. It is employed to relieve pain and reduce fever in adult patients. The medication belongs to the analgesic and antipyretic therapeutic class and is commonly prescribed for moderate to severe pain, postoperative discomfort, and febrile conditions.

GNH USA supplies Metamizol Ratiopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizole sodium is indicated for conditions where pain or fever requires effective control.

Pain: Provides analgesic relief for moderate to severe acute pain. Fever: Reduces elevated body temperature in febrile states. Postoperative pain: Controls pain following surgical procedures.

Metamizole sodium may be associated with a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea - Vomiting - Dizziness - Skin rash

Serious or Rare Side Effects: - Agranulocytosis (severe reduction of white blood cells) - Anaphylactic shock - Stevens‑Johnson syndrome

When prescribing Metamizole sodium, clinicians should observe several precautionary measures to ensure patient safety.

Blood count monitoring: Perform baseline and periodic complete blood counts to detect agranulocytosis early. Hypersensitivity assessment: Avoid use in patients with known allergy to metamizole or other pyrazolones. Pregnancy and lactation: Use only if the potential benefit outweighs unknown risks; safety data are limited. Renal/hepatic impairment: Adjust therapy cautiously and monitor organ function. Concomitant myelotoxic drugs: Exercise caution when combined with other agents that suppress bone marrow. Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Metamizole sodium can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Myelotoxic agents (e.g., cyclophosphamide, chemotherapy): May increase risk of severe blood dyscrasias. - Other NSAIDs or COX inhibitors: Heightened potential for gastrointestinal bleeding and renal impairment. - Anticoagulants (e.g., warfarin): May potentiate anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or diuretics: Combined use can enhance hypotensive effects. - Antihypertensive agents: May require blood pressure monitoring. - Other pyrazolone derivatives: Potential additive risk of agranulocytosis.